

Non Hodgkin Lymphoma Therapeutics Market & Pipeline Insight

<https://marketpublishers.com/r/N7F3EEB8CC1EN.html>

Date: November 2014

Pages: 573

Price: US\$ 2,400.00 (Single User License)

ID: N7F3EEB8CC1EN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

The market for Non Hodgkin Lymphoma has significant unmet medical necessities in terms of demand for innovative drugs and novel technologies. This is one of the major factors behind the market witnessing rapid growth in Non Hodgkin Lymphoma segment. Past few decades have witnessed an increased level of activity with regards to development of new identification systems and drug mechanisms. In recent years, there have been an increasing number of pharmaceutical companies focusing their efforts on developing better and highly effective therapeutics for Non Hodgkin Lymphoma which are likely to occupy major market share in coming years.

Monoclonal antibodies (mAbs) for the treatment of Non Hodgkin Lymphoma has occupied large portion in global market. The highly versatile nature of mAbs makes them suitable for targeting different sub-categories of Non Hodgkin Lymphoma which is modestly provided by other therapeutics. The market of widely used chemotherapeutics is likely to decrease further as they are less effective and have more side effects as compared to mAbs. Present market shows that pharmaceutical companies are trying to capture large market portion by increasing indication of already available mAbs for other cancer categories.

Targeted therapies for Non Hodgkin Lymphoma have been able to make a significant place in global market. These therapeutics are generally based on inhibitors which targets signaling in the cancerous cells. Ibrutinib kinase inhibitor developed by Pharmacyclics and Johnson and Johnson's sub-division Janssen Pharmaceuticals got market approval by the FDA in 2013 for the treatment of mantel cell lymphoma. In 2014, this drug also got the FDA's approval for chronic lymphocytic leukemia in US market. It

is expected that more targeted therapeutics will be available in coming years that would be able to provide effective medical care to patients and generate higher revenues for pharmaceutical companies.

The concepts of personalized cancer vaccines for Non Hodgkin Lymphoma have started emerging in global therapeutic market. These vaccines are widely accepted by oncologists and patients for having higher safety and efficacy levels. However, issues pertaining higher costs of newly developed personalized cancer vaccine is expected to decrease in near future. Technological advances have created higher confidences in pharmaceutical companies to make these medicines at higher manufacturing rates. This capability will help them to increase the market penetration of Non Hodgkin Lymphoma cancer vaccines.

With the recent technological advances, stem cell transplant has emerged as potent method for the treatment and cure of Non-Hodgkin. Oncologists are still trying to decipher the underlying principal of stem cell therapeutics as a treatment strategy. This method is expected to emerge as major section in market as the benefits provided outmatches any other products. It is expected that pharmaceutical companies would be able to overcome barriers in coming years before market introduction.

The market of Non Hodgkin Lymphoma is expected to make steady growth in coming years due to raising incidences and introduction of new therapeutics by pharmaceutical companies in global market. This largely untapped market has yet to witness the products which would be able to prevent, cure this disease, decrease morbidity and mortality rates. Large amount of money invested in research and development has started to show positive effect on pharmaceutical industry. As a result, the introductions of large amount of therapeutic products in coming years are expected to increase global market size of Non Hodgkin Lymphoma therapeutics.

“Non Hodgkin Lymphoma Therapeutics Market & Pipeline Insight” Report Highlight:

Global Non Hodgkin Lymphoma Market Overview

Mechanism of Non Hodgkin Lymphoma Therapeutics

Global Non Hodgkin Lymphoma Pipeline by Type, Phase & Company

Global Non Hodgkin Lymphoma Pipeline: 204 Drugs

Majority of the Drugs are in Phase-I: 54 Drugs

Marketed Drugs for Non Hodgkin Lymphoma: 30 Drugs

Patent Analysis by Country, Year & Compositions

Contents

1. INTRODUCTION TO NON HODGKIN LYMPHOMA

- 1.1 Low Grade Non Hodgkin Lymphomas-
- 1.2 High Grade Non Hodgkin Lymphomas

2. MECHANISM OF NON HODGKIN LYMPHOMA THERAPEUTICS

3. GLOBAL NON HODGKIN LYMPHOMA MARKET OVERVIEW

- 3.1 Current Market Scenario
- 3.2 Global Non Hodgkin Lymphoma Clinical Pipeline Overview

4. GLOBAL NON HODGKIN LYMPHOMA MARKET DYNAMICS

- 4.1 Favorable Market Parameters
- 4.2 Market Growth Challenges
- 4.3 Future Growth Outlook

5. FOLLICULAR LYMPHOMA CLINICAL PIPELINE INSIGHT BY PHASE, INDICATION, COMPANY & COUNTRY

- 5.1 Research till Phase-III
- 5.2 Discontinued Drug in Pipeline

6. NON HODGKIN LYMPHOMA CLINICAL PIPELINE INSIGHT BY PHASE, INDICATION, COMPANY & COUNTRY

- 6.1 Research till Registration
- 6.2 Marketed Drugs Clinical Insight
- 6.3 Suspended & Discontinued Drugs in Clinical Pipeline

7. B-CELL LYMPHOMA CLINICAL PIPELINE INSIGHT BY PHASE, INDICATION, COMPANY & COUNTRY

- 7.1 Preclinical till Phase-II
- 7.2 Discontinued Drugs in Clinical Pipeline

8. MANTLE CELL LYMPHOMA CLINICAL PIPELINE INSIGHT BY PHASE, INDICATION, COMPANY & COUNTRY

8.1 Preclinical till Phase-II

8.2 Discontinued Drugs in Clinical Pipeline

9. CUTANEOUS T CELL LYMPHOMA CLINICAL PIPELINE INSIGHT BY PHASE, INDICATION, COMPANY & COUNTRY

9.1 Preclinical till Phase-II

9.2 Marketed Drug Clinical Insight

9.3 Discontinued Drugs in Clinical Pipeline

10. CUTANEOUS B-CELL LYMPHOMA CLINICAL PIPELINE INSIGHT BY PHASE, INDICATION, COMPANY & COUNTRY

10.1 Phase: Preclinical

11. DIFFUSE LARGE B CELL LYMPHOMA CLINICAL PIPELINE INSIGHT BY PHASE, INDICATION, COMPANY & COUNTRY

11.1 Preclinical till Phase-II

11.2 Discontinued Drugs in Clinical Pipeline

12. T CELL LYMPHOMA CLINICAL PIPELINE INSIGHT BY PHASE, INDICATION, COMPANY & COUNTRY

12.1 Preclinical till Phase-II

12.2 Marketed Drugs Clinical Insight

12.3 Discontinued Drugs in Clinical Pipeline

13. MYCOSIS FUNGOIDES CLINICAL PIPELINE INSIGHT BY PHASE, INDICATION, COMPANY & COUNTRY

13.1 Phase-I

13.2 Marketed Drugs Clinical Insight

14. PERIPHERAL T-CELL LYMPHOMA CLINICAL PIPELINE INSIGHT BY PHASE, INDICATION, COMPANY & COUNTRY

14.1 Phase-II

15. MULTIPLE NON HODGKIN LYMPHOMA CLINICAL PIPELINE INSIGHT BY PHASE, INDICATION, COMPANY & COUNTRY

15.1 Preclinical till Registration

15.2 Marketed Drugs Clinical Insight

15.3 Discontinued Drugs in Clinical Pipeline

16. COMPETITIVE LANDSCAPE

16.1 Aryogen Biopharma

16.2 Biogen Idec

16.3 Biovest International

16.4 Chugai Pharmaceutical

16.5 Genetech

16.6 ImmunoGen

16.7 Johnson & Johnson

16.8 Novartis

16.9 Pfizer

16.10 Roche

List Of Figures

LIST OF FIGURES

Figure 1-1: Types of Blood Cancer

Figure 1-2: Identification of Different Types of Lymphomas

Figure 1-3: Classification Systems for Non Hodgkin Lymphoma

Figure 1-4: Grading of Non Hodgkin Lymphomas

Figure 1-5: Classification of Low Grade Non Hodgkin Lymphomas

Figure 1-6: Classification of High Grade Non Hodgkin Lymphomas

Figure 2-1: Mechanism of Monoclonal Antibodies for the Treatment of Non Hodgkin Lymphoma

Figure 2-2: Mechanism of Kinase Inhibitors for Treating Non- Hodgkin Lymphoma

Figure 2-3: Mode of Action of Non Hodgkin Lymphoma Vaccines

Figure 3-1: Non-Hodgkin Lymphoma Therapeutics Market (US\$ Billion), 2014-2020

Figure 3-2: Follicular Lymphoma Clinical Pipeline by Phase (%), 2014

Figure 3-3: Follicular Lymphoma Clinical Pipeline by Phase (Number), 2014

Figure 3-4: Discontinued Follicular Lymphoma Clinical Pipeline by Phase (%), 2014

Figure 3-5: Discontinued Follicular Lymphoma Clinical Pipeline by Phase (Number), 2014

Figure 3-6: Non Hodgkin Lymphoma Clinical Pipeline by Phase (%), 2014

Figure 3-7: Non Hodgkin Lymphoma Clinical Pipeline by Phase (Number), 2014

Figure 3-8: No Development Reported in Non Hodgkin Lymphoma Clinical Pipeline by Phase (%), 2014

Figure 3-9: No Development Reported in Non Hodgkin Lymphoma Clinical Pipeline by Phase (Number), 2014

Figure 3-10: Discontinued Non Hodgkin Lymphoma Clinical Pipeline by Phase (%), 2014

Figure 3-11: Discontinued Non Hodgkin Lymphoma Clinical Pipeline by Phase (Number), 2014

Figure 3-12: Suspended Non Hodgkin Lymphoma Clinical Pipeline by Phase (%), 2014

Figure 3-13: Suspended Non Hodgkin Lymphoma Clinical Pipeline by Phase (Number), 2014

Figure 3-14: B-Cell Lymphoma Clinical Pipeline by Phase (%), 2014

Figure 3-15: B-Cell Lymphoma Clinical Pipeline by Phase (Number), 2014

Figure 3-16: No Development Reported in B-Cell Lymphoma Clinical Pipeline by Phase (%), 2014

Figure 3-17: No Development Reported in B-Cell Lymphoma Clinical Pipeline by Phase (Number), 2014

- Figure 3-18: Discontinued B-Cell Lymphoma Clinical Pipeline by Phase (%), 2014
- Figure 3-19: Discontinued B-Cell Lymphoma Clinical Pipeline by Phase (Number), 2014
- Figure 3-20: Mantle-Cell Lymphoma Clinical Pipeline by Phase (%), 2014
- Figure 3-21: Mantle-Cell Lymphoma Clinical Pipeline by Phase (Number), 2014
- Figure 3-22: Cutaneous T-Cell Lymphoma Clinical Pipeline by Phase (%), 2014
- Figure 3-23: Cutaneous T-Cell Lymphoma Clinical Pipeline by Phase (Number), 2014
- Figure 3-24: Discontinued Cutaneous T-Cell Lymphoma Clinical Pipeline by Phase (%), 2014
- Figure 3-25: Discontinued Cutaneous T-Cell Lymphoma Clinical Pipeline by Phase (Number), 2014
- Figure 3-26: Diffuse Large B-Cell Lymphoma Clinical Pipeline by Phase (%), 2014
- Figure 3-27: Diffuse Large B-Cell Lymphoma Clinical Pipeline by Phase (Number), 2014
- Figure 3-28: Discontinued Diffuse Large B-Cell Lymphoma Clinical Pipeline by Phase (%), 2014
- Figure 3-29: Discontinued Diffuse Large B-Cell Lymphoma Clinical Pipeline by Phase (Number), 2014
- Figure 3-30: T-Cell Lymphoma Clinical Pipeline by Phase (%), 2014
- Figure 3-31: T-Cell Lymphoma Clinical Pipeline by Phase (Number), 2014
- Figure 3-32: Mycosis Fungoides Clinical Pipeline by Phase (%), 2014
- Figure 3-33: Mycosis Fungoides Clinical Pipeline by Phase (Number), 2014
- Figure 3-34: Multiple Non Hodgkin Lymphoma Clinical Pipeline by Phase (%), 2014
- Figure 3-35: Multiple Non Hodgkin Lymphoma Clinical Pipeline by Phase (Number), 2014
- Figure 3-36: Discontinued Multiple Non Hodgkin Lymphoma Clinical Pipeline by Phase (%), 2014
- Figure 3-37: Discontinued Multiple Non Hodgkin Lymphoma Clinical Pipeline by Phase (Number), 2014
- Figure 4-1: Drivers for Non- Hodgkin Lymphoma Market
- Figure 4-2: Challenges for Non- Hodgkin Lymphoma Market

I would like to order

Product name: Non Hodgkin Lymphoma Therapeutics Market & Pipeline Insight

Product link: <https://marketpublishers.com/r/N7F3EEB8CC1EN.html>

Price: US\$ 2,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N7F3EEB8CC1EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970